Profil bibliographique

Aparna R. Parikh

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

582Publications signalées

8905Citations signalées

3Affiliations récentes

Institutions déclarées

Harvard University Massachusetts General Hospital Center for Cancer Research

Domaines associés

Colorectal Cancer Treatments and StudiesCancer Genomics and DiagnosticsImmunotherapy and Immune Responsesvaccines and immunoinformatics approachesViral-associated cancers and disorders

Publications récentes

2026 articleOpenAlex

INCA033890-303: A randomized, double-blind, phase 3 study of FOLFOX and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite-stable colorectal cancer.

Van K. Morris, Miguel Colon Donate, Jenny Seligmann, Atsuo Takashima et autres

0 citationsJournal of Clinical Oncology

2026 conference-abstractOpenAlex

PRTH-101: An investigational treatment for thoracic solid tumors targeting discoidin domain receptor (DDR1) and the tumor microenvironment (TME).

Funda Meric-Bernstam, So Yeon Kim, Shiraj Sen, Christopher Sheild Nabel et autres

0 citationsJournal of Clinical Oncology

2026 articleOpenAlex

A phase 2 randomized study comparing telisotuzumab adizutecan monotherapy with standard of care in patients with post-adjuvant circulating tumor DNA–positive colorectal cancer.

Kanwal Pratap Singh Raghav, Hideaki Bando, Tao-Wei Ke, Meredith Pelster et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2026 conference-abstractOpenAlex

A randomized, active-controlled phase 3 study of ivonescimab + FOLFOX versus bevacizumab + FOLFOX as first-line treatment of metastatic colorectal cancer (mCRC): HARMONi-GI3.

Aparna R. Parikh, Michael J. Overman, Christopher T. Chen, E Elez et autres

0 citationsJournal of Clinical Oncology

2026 conference-abstractOpenAlex

Correlative analysis of ctDNA in CheckMate-9X8 study of frontline treatment with mFOLFOX6, bevacizumab with or without nivolumab in metastatic colorectal cancer.

Jin Yao, Yong Huang, Rachel Tam, Amanda Cruz et autres

0 citationsJournal of Clinical Oncology

2026 conference-abstractOpenAlex

Real-world experiences with a multi-cancer detection (MCD) blood test.

Julius Chiang-Boeckmann, Erica T. Warner, Aparna R. Parikh, D. Michael Miller et autres

0 citationsJournal of Clinical Oncology

2026 conference-abstractOpenAlex

A phase II study of FOLFIRINOX (FFX) combined with the glycogen synthase kinase-3beta (GSK-3β) inhibitor elraglusib (ELRA) and the transforming growth factor beta (TGFβ) inhibitor losartan (LOS) in patients with untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).

Priyadarshini Satyajit Pathak, Elizabeth P. Walsh, Kelsey S. Lau‐Min, Bennett Adam Caughey et autres

0 citationsJournal of Clinical Oncology

2026 articleOpenAlex

Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors

E. E. Dumbrava, Geoffrey I. Shapiro, Aparna R. Parikh, Melissa L. Johnson et autres

20 citationsNew England Journal of Medicine

Accès ouvert 2026 conference-abstractOpenAlex

Tolerability and outcomes after neoadjuvant and definitive radiation of elderly patients with localized pancreatic cancer.

Celia Blaszkowsky, Priyadarshini Satyajit Pathak, Zoe Guan, Beow Y. Yeap et autres

0 citationsJournal of Clinical Oncology

2026 conference-abstractOpenAlex

A phase 2 randomized study comparing telisotuzumab adizutecan monotherapy with standard of care in patients with post-adjuvant circulating tumor DNA-positive colorectal cancer.

K. Raghav, Hideaki Bando, Taowei Ke, Meredith Pelster et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2026 conference-abstractOpenAlex

A phase 1/2 study of revumenib in patients (pts) with advanced colorectal cancer (CRC) and other solid tumors.

Aparna R. Parikh, Kristen Keon Ciombor, Nashat Y. Gabrail, Jessica M. Clement et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2026 articleOpenAlex

Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators

Ferran Fece de la Cruz, Andreas Varkaris, Parasvi S. Patel, Elijah W. Kushner et autres

6 citationsCancer Discovery

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.